Zynex Inc is a medical technology company that specializes in the development and manufacturing of non-invasive medical devices, primarily focused on pain management and rehabilitation
The company's innovative products include electrotherapy devices that utilize neuromuscular electrical stimulation to help patients manage acute and chronic pain, as well as devices designed to aid in physical therapy and recovery. Zynex is committed to improving patient outcomes through its advanced technology and is actively involved in expanding its offerings to meet the growing needs of the healthcare market.
Law Offices of Howard G. Smith reminds investors of the upcoming May 19, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, inclusive (the “Class Period”).
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ:ZYXI) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Zynex securities between March 13, 2023 and March 11, 2025, both dates inclusive (the “Class Period”). Investors have until May 19, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYXI) securities between March 13, 2023 to March 11, 2025. Zynex is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management and physical rehabilitation.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) and reminds investors of the May 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Glancy Prongay & Murray LLP reminds investors of the upcoming May 19, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, inclusive (the “Class Period”).
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, inclusive (the “Class Period”). Zynex investors have until May 19, 2025 to file a lead plaintiff motion.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zynex, Inc. (“Zynex” or “the Company”) (NASDAQ: ZYXI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, inclusive (the “Class Period”). Zynex investors have until May 19, 2025 to file a lead plaintiff motion.
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the District of Colorado, captioned Tuncel v. Zynex, Inc., et al., Case No. 25-cv-00913, on behalf of persons and entities that purchased or otherwise acquired Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith continues its investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz continues its investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Demand for pain management devices is climbing worldwide, fueled by several major trends. As chronic disease rates soar, the need for effective, drug-free pain solutions has grown more pressing. At the same time, advancements in medical tech have opened doors to safer, non-invasive pain relief options, making them more widely adopted by healthcare providers. Rising numbers of surgeries have also created a strong demand for post-operative pain control, while the pain monitoring market continues to surge. With these combined factors, the global pain management device market is expected to reach $5.68 billion by 2032, expanding at a steady 9% CAGR.
